A citation-based method for searching scientific literature

Daniel J Cuthbertson, Andrew Irwin, Chris J Gardner, Christina Daousi, Tej Purewal, Niall Furlong, Niru Goenka, E Louise Thomas, Valerie L Adams, Sudeep P Pushpakom, Munir Pirmohamed, Graham J Kemp. PLoS One 2012
Times Cited: 143







List of co-cited articles
1009 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
749
47

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
Nitika Arora Gupta, Jamie Mells, Richard M Dunham, Arash Grakoui, Jeffrey Handy, Neeraj Kumar Saxena, Frank A Anania. Hepatology 2010
299
34

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Gianluca Svegliati-Baroni, Stefania Saccomanno, Chiara Rychlicki, Laura Agostinelli, Samuele De Minicis, Cinzia Candelaresi, Graziella Faraci, Deborah Pacetti, Marco Vivarelli, Daniele Nicolini,[...]. Liver Int 2011
257
31

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Xiaokun Ding, Neeraj K Saxena, Songbai Lin, Nitika Arora Gupta, Frank A Anania. Hepatology 2006
383
27

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J).
Yuichiro Eguchi, Yoichiro Kitajima, Hideyuki Hyogo, Hirokazu Takahashi, Motoyasu Kojima, Masafumi Ono, Norimasa Araki, Kenichi Tanaka, Miyuki Yamaguchi, Yayoi Matsuda,[...]. Hepatol Res 2015
102
27


Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
Jean-Michel Petit, Jean-Pierre Cercueil, Romaric Loffroy, Damien Denimal, Benjamin Bouillet, Coralie Fourmont, Olivier Chevallier, Laurence Duvillard, Bruno Vergès. J Clin Endocrinol Metab 2017
93
25

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.
Shani Ben-Shlomo, Isabel Zvibel, Mati Shnell, Amir Shlomai, Elena Chepurko, Zamir Halpern, Nir Barzilai, Ran Oren, Sigal Fishman. J Hepatol 2011
188
22

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Takamasa Ohki, Akihiro Isogawa, Masahiko Iwamoto, Mitsuru Ohsugi, Haruhiko Yoshida, Nobuo Toda, Kazumi Tagawa, Masao Omata, Kazuhiko Koike. ScientificWorldJournal 2012
74
29

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
An Tang, Rémi Rabasa-Lhoret, Hélène Castel, Claire Wartelle-Bladou, Guillaume Gilbert, Karine Massicotte-Tisluck, Gabriel Chartrand, Damien Olivié, Anne-Sophie Julien, Jacques de Guise,[...]. Diabetes Care 2015
71
29

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
M J Armstrong, D D Houlihan, I A Rowe, W H O Clausen, B Elbrønd, S C L Gough, J W Tomlinson, P N Newsome. Aliment Pharmacol Ther 2013
145
20


Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
James L Trevaskis, Peter S Griffin, Carrie Wittmer, Brent A Neuschwander-Tetri, Elizabeth M Brunt, Carrie S Dolman, Mary R Erickson, James Napora, David G Parkes, Jonathan D Roth. Am J Physiol Gastrointest Liver Physiol 2012
152
19

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
Ning Shao, Hong Yu Kuang, Ming Hao, Xin Yuan Gao, Wen Jian Lin, Wei Zou. Diabetes Metab Res Rev 2014
101
19

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
18

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
Daisuke Suzuki, Masao Toyoda, Moritugu Kimura, Masaaki Miyauchi, Naoyuki Yamamoto, Hiroki Sato, Eitaro Tanaka, Yusuke Kuriyama, Han Miyatake, Makiko Abe,[...]. Intern Med 2013
41
41

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Renata Belfort, Stephen A Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin Tio, Joseph Pulcini,[...]. N Engl J Med 2006
17

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Matthew J Armstrong, Diana Hull, Kathy Guo, Darren Barton, Jonathan M Hazlehurst, Laura L Gathercole, Maryam Nasiri, Jinglei Yu, Stephen C Gough, Philip N Newsome,[...]. J Hepatol 2016
172
17

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
Patrick R Kenny, Daniel E Brady, Dawn M Torres, Linda Ragozzino, Naga Chalasani, Stephen A Harrison. Am J Gastroenterol 2010
80
20

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, Petra J W Pouwels, Indra C Pieters-van den Bos, Trynke Hoekstra, Michaela Diamant, Daniël H van Raalte, Djuna L Cahen. Diabetologia 2016
65
24

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
514
15

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Padma Sathyanarayana, Medhavi Jogi, Raja Muthupillai, Ramkumar Krishnamurthy, Susan L Samson, Mandeep Bajaj. Obesity (Silver Spring) 2011
70
21

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
15

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.
Hui Fan, QingRong Pan, Yuan Xu, XinChun Yang. Arq Bras Endocrinol Metabol 2013
62
24

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
Jamie E Mells, Ping P Fu, Shvetank Sharma, Darin Olson, Lihong Cheng, Jeffrey A Handy, Neeraj K Saxena, Dan Sorescu, Frank A Anania. Am J Physiol Gastrointest Liver Physiol 2012
147
14

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
Yan Bi, Bing Zhang, Wen Xu, Huijie Yang, Wenhuan Feng, Cuiliu Li, Guoyu Tong, Ming Li, Xin Wang, Shanmei Shen,[...]. Acta Diabetol 2014
41
34

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
14

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
745
12

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
783
12


The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
12

Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Yusuf Yilmaz, Oya Yonal, Oguzhan Deyneli, Cigdem Ataizi Celikel, Cem Kalayci, Deniz Guney Duman. Acta Gastroenterol Belg 2012
85
12

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.
Kittichai Promrat, David E Kleiner, Heather M Niemeier, Elizabeth Jackvony, Marie Kearns, Jack R Wands, Joseph L Fava, Rena R Wing. Hepatology 2010
715
11

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C Klonoff, John B Buse, Loretta L Nielsen, Xuesong Guan, Christopher L Bowlus, John H Holcombe, Matthew E Wintle, David G Maggs. Curr Med Res Opin 2008
550
11


Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Wenhuan Feng, Caixia Gao, Yan Bi, Min Wu, Ping Li, Shanmei Shen, Wei Chen, Tingting Yin, Dalong Zhu. J Diabetes 2017
57
19

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Jinhua Yan, Bin Yao, Hongyu Kuang, Xubin Yang, Qin Huang, Tianpei Hong, Yushu Li, Jingtao Dou, Wenying Yang, Guijun Qin,[...]. Hepatology 2019
61
18


Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
Christine Bernsmeier, Anne C Meyer-Gerspach, Lea S Blaser, Lia Jeker, Robert E Steinert, Markus H Heim, Christoph Beglinger. PLoS One 2014
60
16

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus.
Tomoyuki Iwasaki, Masato Yoneda, Masahiko Inamori, Jun Shirakawa, Takuma Higurashi, Shin Maeda, Yasuo Terauchi, Atsushi Nakajima. Hepatogastroenterology 2011
86
11


A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
715
10

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Jeffrey Cui, Len Philo, Phirum Nguyen, Heather Hofflich, Carolyn Hernandez, Ricki Bettencourt, Lisa Richards, Joanie Salotti, Archana Bhatt, Jonathan Hooker,[...]. J Hepatol 2016
180
10


Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
Kerry L Donnelly, Coleman I Smith, Sarah J Schwarzenberg, Jose Jessurun, Mark D Boldt, Elizabeth J Parks. J Clin Invest 2005
9


SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis.
Fen Xu, Zhuo Li, Xiaobin Zheng, Hongxia Liu, Hua Liang, Haixia Xu, Zonglan Chen, Kejing Zeng, Jianping Weng. Diabetes 2014
69
13

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.
Kitt Falk Petersen, Sylvie Dufour, Douglas Befroy, Michael Lehrke, Rosa E Hendler, Gerald I Shulman. Diabetes 2005
582
9

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
476
9

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
Naim Panjwani, Erin E Mulvihill, Christine Longuet, Bernardo Yusta, Jonathan E Campbell, Theodore J Brown, Catherine Streutker, Dianne Holland, Xiemin Cao, Laurie L Baggio,[...]. Endocrinology 2013
220
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.